Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | NOS3 | P29474 | 3/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.39 |
| ▸ | CCR8 | P51685 | 3/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19660068 | 0.82 | NOS3 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL21649892 | 0.82 | NOS3 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL9160147 | 0.81 | NOS2 (0.48) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL2085241 | 0.79 | NOS2 (0.46) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL24465856 | 0.76 | NOS3 (0.43) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL14878068 | 0.76 | NOS3 (0.43) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL21649995 | 0.73 | NOS3 (0.41) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL661299 | 0.71 | — | — | |
| SCHEMBL18782544 | 0.71 | NOS3 (0.39) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL28991160 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471782-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AGTR2, AGTR1, PPARA | NOS2 939/4885NOS3 1223/4885CCR1 1447/4885 |
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | NOS2 2368/4885NOS3 1654/4885CCR1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.